Key result
Kv7 potassium channels are expressed in airway smooth muscle cells, and their pharmacological activation relieves bronchoconstrictor-induced airway constriction.
Kv7 channels in airway smooth muscle cells regulate airway diameter and represent potential pharmacological targets for bronchodilator therapy.
Answers are grounded in this paper and cite their sources.
May support Kv7 activators as bronchodilator targets; hypothesis-generating from animal data and requires human validation.
Expression and function of Kv7 (KCNQ) voltage-activated potassium channels in guinea pig and human airway smooth muscle cells (ASMCs) were investigated by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), patch-clamp electrophysiology, and precision-cut lung slices. qRT-PCR revealed expression of multiple KCNQ genes in both guinea pig and human ASMCs. Currents with electrophysiological and pharmacological characteristics of Kv7 currents were measured in freshly isolated guinea pig and human ASMCs. In guinea pig ASMCs, Kv7 currents were significantly suppressed by application of the bronchoconstrictor agonists methacholine (100 nM) or histamine (30 μM), but current amplitudes were restored by addition of a Kv7 channel activator, flupirtine (10 μM). Kv7 currents in guinea pig ASMCs were also significantly enhanced by another Kv7.2-7.5 channel activator, retigabine, and by celecoxib and 2,5-dimethyl celecoxib. In precision-cut human lung slices, constriction of airways by histamine was significantly reduced in the presence of flupirtine. Kv7 currents in both guinea pig and human ASMCs were inhibited by the Kv7 channel blocker XE991. In human lung slices, XE991 induced robust airway constriction, which was completely reversed by addition of the calcium channel blocker verapamil. These findings suggest that Kv7 channels in ASMCs play an essential role in the regulation of airway diameter and may be targeted pharmacologically to relieve airway hyperconstriction induced by elevated concentrations of bronchoconstrictor agonists.
No takes yet. Share an insight, caveat, or question.
Brueggemann et al. (2011) studied Airway hyperconstriction (preclinical). Kv7 channel modulators (flupirtine, retigabine, XE991) vs. Baseline/Control was evaluated on Kv7 potassium currents and airway luminal area. Kv7 potassium channels are expressed in airway smooth muscle cells, and their pharmacological activation relieves bronchoconstrictor-induced airway constriction.
Synapse has enriched 10 related papers. Consider them for comparative context: